Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10293103" target="_blank" >RIV/00064203:_____/14:10293103 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11130/14:10293103
Výsledek na webu
<a href="http://dx.doi.org/10.1016/j.eururo.2014.06.037" target="_blank" >http://dx.doi.org/10.1016/j.eururo.2014.06.037</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.eururo.2014.06.037" target="_blank" >10.1016/j.eururo.2014.06.037</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations
Popis výsledku v původním jazyce
Context: Non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence risk, partly because of the persistence of lesions following transurethral resection of bladder tumour (TURBT) due to the presence of multiple lesions and the difficulty in identifying the exact extent and location of tumours using standard white-light cystoscopy (WLC). Hexaminolevulinate (HAL) is an optical-imaging agent used with blue-light cystoscopy (BLC) in NMIBC diagnosis. Increasing evidence from long-term follow-up confirms the benefits of BLC over WLC in terms of increased detection and reduced recurrence rates. Objective: To provide updated expert guidance on the optimal use of HAL-guided cystoscopy in clinical practice to improve management of patients with NMIBC, based on a review of the most recent data on clinical and cost effectiveness and expert input. Evidence acquisition: PubMed and conference searches, supplemented by personal experience. Evidence synthesis: Based on published da
Název v anglickém jazyce
Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations
Popis výsledku anglicky
Context: Non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence risk, partly because of the persistence of lesions following transurethral resection of bladder tumour (TURBT) due to the presence of multiple lesions and the difficulty in identifying the exact extent and location of tumours using standard white-light cystoscopy (WLC). Hexaminolevulinate (HAL) is an optical-imaging agent used with blue-light cystoscopy (BLC) in NMIBC diagnosis. Increasing evidence from long-term follow-up confirms the benefits of BLC over WLC in terms of increased detection and reduced recurrence rates. Objective: To provide updated expert guidance on the optimal use of HAL-guided cystoscopy in clinical practice to improve management of patients with NMIBC, based on a review of the most recent data on clinical and cost effectiveness and expert input. Evidence acquisition: PubMed and conference searches, supplemented by personal experience. Evidence synthesis: Based on published da
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
European Urology
ISSN
0302-2838
e-ISSN
—
Svazek periodika
66
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
9
Strana od-do
863-871
Kód UT WoS článku
000344693500022
EID výsledku v databázi Scopus
—